Prestige BioPharma Limited (950210) Fair Value & Analysis
Healthcare · KR · Market cap 306B KRW
Fair value as of: Jul 22, 2026
From 10 valuation models · updated 19 days ago
Share price +14.6% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from 5,552 KRW (bear) to 7,876 KRW (bull), base 6,300 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 42/100 (below-average quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 5,030 KRW – 40,000 KRW · fair‑value band 5,552 KRW – 7,876 KRW · the 6,600 KRW price screens above the 6,300 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Prestige BioPharma Limited (950210) currently trades at 6,600 KRW, while our model-based Fair Value estimate is 6,300 KRW, implying the stock looks roughly 4.5% fairly valued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at 16.2B KRW. Revenue declined 84.8% year over year. It earns a return on equity of -14.5%. Net debt stands at 28.7B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 5,552 KRW (bear case) to 7,876 KRW (bull case); at 6,600 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -5%, 950210 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Growth Earnings (16,715 KRW) versus DCF Models (3,554 KRW). Highest evidence: Growth-Adj P/E (68).
Notify me when 950210 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 44 · Market factors (momentum, volatility) 21
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore.
Full company description
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis; and IDC007, a bispecific antibody for the treatment of CRS. In addition, the company is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies; IDC111, a first-in-class antibody; IDC112, first-in-class antibody; IDC113 first-in-class antibody; IDC332, IDC331, IDC333, and IDC334 novel concept antibodies; and IDC441, an ADC antibody for the treatment of solid tumours. Additionally, it offers biosimilars for immunology, endocrinology, oncology, haematology, and dermatology diseases. Further, it develops IDC221, a PAUF-based pancreatic cancer diagnostic solution for the treatment of pancreatic cancers. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2025 · reported fiscal years
Prestige BioPharma Limited reported revenue of 14.3B KRW in FY2025 versus 2.1B KRW in FY2019, a compound +37.8%/yr. Reported net income was 22.3B KRW in FY2025.
Watch 950210: get an alert when its fair value changes →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Prestige BioPharma Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Prestige BioPharma Limited (950210) overvalued or undervalued?
What is the fair value of 950210?
What is the quality score of 950210?
What is the revenue of Prestige BioPharma Limited (950210)?
What is the net profit margin of 950210?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Prestige BioPharma Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.